Bio-Rad Laboratories, Inc. (BIO.B) shareholders
BIO.BNYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/3055% above fair value
$379.50+0.00 (0.00%)
Close on Oct 29, 2026Market cap $10.18BP/E 46.2Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 5M shares
Institutional holders
5
0 new, 2 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $349.88K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Norman D. Schwartz Joint filing with Alice N. Schwartz Revocable Trust (8.10%) | 3,228,922 | 14.60% | 13D (active) amendment | Sep 25, 2025 |
| Alice N. Schwartz Joint filing with Alice N. Schwartz Revocable Trust (8.00%) | 2,732,073 | 12.30% | 13D (active) amendment | May 1, 2025 |
| First Eagle Investment Management, LLC Joint filing with First Eagle Global Fund (8.50%) | 2,528,321 | 11.40% | 13G (passive) amendment | Jun 30, 2025 |
| The Vanguard Group - 23-1945930 | 1,907,640 | 8.37% | 13G (passive) amendment | Sep 30, 2024 |
| BlackRock, Inc. | 1,618,123 | 7.40% | 13G (passive) amendment | Sep 30, 2025 |
| Van Eck Associates Corporation 666 Third Ave. - 9th Floor, New York, New York 10017 | 1,306,473 | 5.73% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BIO.B | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Flow Traders U.S. LLC | 760 | 0.02% | $229.00K | −225 | 0.01% |
| Morgan Stanley | 712 | 0.01% | $214.31K | – | 0.00% |
| Wells Fargo & Company/Mn | 170 | 0.00% | $50.40K | – | 0.00% |
| Whittier Trust Co | 160 | 0.00% | $47.29K | – | 0.00% |
| UBS Group AG | 13 | 0.00% | $3.91K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 5 | 0M | 0.0% | 0 / 0 | 1 / 2 | 0M | 0M |
| Q1 2026 | 7 | 0M | 0.1% | 1 / 2 | 1 / 0 | 0M | 0M |
| Q4 2025 | 6 | 0M | 0.1% | 1 / 0 | 2 / 0 | 0M | 0M |
| Q3 2025 | 5 | 0M | 0.1% | 1 / 0 | 0 / 1 | 0M | 0M |
| Q2 2025 | 5 | 0M | 0.0% | 0 / 1 | 0 / 0 | 0M | 0M |
| Q1 2025 | 5 | 0M | 0.0% | 0 / 0 | 1 / 3 | 0M | 0M |
| Q4 2024 | 8 | 0M | 0.1% | 2 / 1 | 1 / 0 | 0M | 0M |
| Q3 2024 | 6 | 0M | 0.1% | 1 / 1 | 1 / 2 | 0M | 0M |
| Q2 2024 | 8 | 0M | 0.1% | 1 / 0 | 2 / 0 | 0M | 0M |
| Q1 2024 | 7 | 0M | 0.1% | 1 / 1 | 1 / 0 | 0M | 0M |
| Q4 2023 | 6 | 0M | 0.1% | 0 / 1 | 1 / 2 | 0M | 0M |
| Q3 2023 | 8 | 0M | 0.1% | 1 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Norman D. Schwartz | Chairman & CEO, Director, 10% owner | 7,696,966 | 152.08% | Sep 9, 2026 |
| Jonathan P. DiVincenzo | President & COO | 2,631 | 0.05% | Sep 9, 2026 |
| Roop Kalyan Lakkaraju | EVP, Chief Financial Officer | 4,151 | 0.08% | Sep 9, 2026 |
| Sedat Evran | EVP, Global Supply Chain | 3,880 | 0.08% | Sep 9, 2026 |
| James Barry | EVP, President, LSG | 2,025 | 0.04% | Sep 9, 2026 |
| Eva Anette Engelhardt | EVP, President, CDG | 1,828 | 0.04% | Sep 9, 2026 |
| Courtney C. Enloe | EVP, General Counsel & Sec | 1,652 | 0.03% | Sep 9, 2026 |
| Rajat Mehta | EVP, GBL Commercial Operations | 1,232 | 0.02% | Sep 9, 2026 |
| Colleen Corey | EVP, Global Human Resources | 19,550 | 0.39% | Sep 9, 2025 |
| Michael Crowley | EVP, GBL Commercial Operations | 8,171 | 0.16% | Mar 18, 2025 |
| Schwartz Allison | Director | 1,768 | 0.03% | Sep 9, 2026 |
| Melinda Litherland Pei | Director | 715 | 0.01% | Apr 23, 2026 |
| Jeffrey L. Edwards | Director | 715 | 0.01% | Apr 23, 2026 |
| Greg K. Hinckley | Director | 1,215 | 0.02% | Apr 23, 2026 |
| Arnold A. Pinkston | Director | 715 | 0.01% | Apr 23, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Courtney C. Enloe EVP, General Counsel & Sec | Sep 6, 2026 | Tax withholding | −305 | $386.11 | $117.76K | 1,652 |
| Courtney C. Enloe EVP, General Counsel & Sec | Sep 6, 2026 | Option exercise | +768 | – | – | 1,957 |
| Eva Anette Engelhardt EVP, President, CDG | Sep 6, 2026 | Tax withholding | −485 | $386.11 | $187.26K | 1,828 |
| Eva Anette Engelhardt EVP, President, CDG | Sep 6, 2026 | Option exercise | +1,152 | – | – | 2,313 |
| Schwartz Allison Director | Sep 6, 2026 | Option exercise | +92 | – | – | 1,768 |
| Schwartz Allison Director | Sep 6, 2026 | Tax withholding | −34 | $386.11 | $13.13K | 1,734 |
| James Barry EVP, President, LSG | Sep 6, 2026 | Tax withholding | −470 | $386.11 | $181.47K | 2,025 |
| James Barry EVP, President, LSG | Sep 6, 2026 | Option exercise | +1,056 | – | – | 2,495 |
| Sedat Evran EVP, Global Supply Chain | Sep 6, 2026 | Option exercise | +864 | – | – | 3,880 |
| Sedat Evran EVP, Global Supply Chain | Sep 6, 2026 | Tax withholding | −277 | $386.11 | $106.95K | 3,603 |
| Roop Kalyan Lakkaraju EVP, Chief Financial Officer | Sep 6, 2026 | Tax withholding | −782 | $386.11 | $301.94K | 4,151 |
| Roop Kalyan Lakkaraju EVP, Chief Financial Officer | Sep 6, 2026 | Option exercise | +1,536 | – | – | 4,933 |
| Norman D. Schwartz Chairman & CEO, Director, 10% owner | Sep 6, 2026 | Tax withholding | −1,854 | $386.11 | $715.85K | 449,019 |
| Norman D. Schwartz Chairman & CEO, Director, 10% owner | Sep 6, 2026 | Option exercise | +3,455 | – | – | 450,873 |
| Rajat Mehta EVP, GBL Commercial Operations | Sep 5, 2026 | Tax withholding | −504 | $386.11 | $194.60K | 1,232 |
| Rajat Mehta EVP, GBL Commercial Operations | Sep 5, 2026 | Option exercise | +1,370 | – | – | 1,736 |
| Rajat Mehta EVP, GBL Commercial Operations | Sep 5, 2026 | Tax withholding | −233 | $386.11 | $89.96K | 366 |
| Rajat Mehta EVP, GBL Commercial Operations | Sep 5, 2026 | Option exercise | +456 | – | – | 599 |
| Courtney C. Enloe EVP, General Counsel & Sec | Sep 5, 2026 | Tax withholding | −246 | $386.11 | $94.98K | 1,189 |
| Courtney C. Enloe EVP, General Counsel & Sec | Sep 5, 2026 | Option exercise | +685 | – | – | 1,435 |
| Eva Anette Engelhardt EVP, President, CDG | Sep 5, 2026 | Tax withholding | −369 | $386.11 | $142.47K | 1,161 |
| Eva Anette Engelhardt EVP, President, CDG | Sep 5, 2026 | Option exercise | +1,027 | – | – | 1,530 |
| Schwartz Allison Director | Sep 5, 2026 | Tax withholding | −82 | $386.11 | $31.66K | 1,676 |
| Schwartz Allison Director | Sep 5, 2026 | Option exercise | +228 | – | – | 1,758 |
| James Barry EVP, President, LSG | Sep 5, 2026 | Option exercise | +1,027 | – | – | 1,808 |
| James Barry EVP, President, LSG | Sep 5, 2026 | Tax withholding | −369 | $386.11 | $142.47K | 1,439 |
| Sedat Evran EVP, Global Supply Chain | Sep 5, 2026 | Option exercise | +1,027 | – | – | 3,345 |
| Sedat Evran EVP, Global Supply Chain | Sep 5, 2026 | Tax withholding | −329 | $386.11 | $127.03K | 3,016 |
| Roop Kalyan Lakkaraju EVP, Chief Financial Officer | Sep 5, 2026 | Option exercise | +1,370 | – | – | 3,956 |
| Roop Kalyan Lakkaraju EVP, Chief Financial Officer | Sep 5, 2026 | Tax withholding | −559 | $386.11 | $215.84K | 3,397 |
| Jonathan P. DiVincenzo President & COO | Sep 5, 2026 | Option exercise | +1,712 | – | – | 2,631 |
| Jonathan P. DiVincenzo President & COO | Sep 5, 2026 | Tax withholding | −668 | $386.11 | $257.92K | 1,963 |
| Norman D. Schwartz Chairman & CEO, Director, 10% owner | Sep 5, 2026 | Option exercise | +4,109 | – | – | 450,294 |
| Norman D. Schwartz Chairman & CEO, Director, 10% owner | Sep 5, 2026 | Tax withholding | −2,876 | $386.11 | $1.11M | 447,418 |
| James Barry EVP, President, LSG | Sep 1, 2026 | Tax withholding | −154 | $380.96 | $58.67K | 781 |
| James Barry EVP, President, LSG | Sep 1, 2026 | Option exercise | +425 | – | – | 935 |
| Schwartz Allison Director | Sep 1, 2026 | Option exercise | +117 | – | – | 1,573 |
| Schwartz Allison Director | Sep 1, 2026 | Tax withholding | −43 | $380.96 | $16.38K | 1,530 |
| Norman D. Schwartz Chairman & CEO, Director, 10% owner | Sep 1, 2026 | Tax withholding | −2,336 | $380.96 | $889.92K | 446,185 |
| Norman D. Schwartz Chairman & CEO, Director, 10% owner | Sep 1, 2026 | Option exercise | +5,087 | – | – | 448,521 |
| Eva Anette Engelhardt EVP, President, CDG | Jul 25, 2026 | Option exercise | +246 | – | – | 592 |
| Eva Anette Engelhardt EVP, President, CDG | Jul 25, 2026 | Tax withholding | −89 | $314.46 | $27.99K | 503 |
| Eva Anette Engelhardt EVP, President, CDG | May 11, 2026 | Sale | −550 | $246.54 | $135.60K | 346 |
| Courtney C. Enloe EVP, General Counsel & Sec | Apr 24, 2026 | Tax withholding | −77 | $287.84 | $22.16K | 750 |
| Courtney C. Enloe EVP, General Counsel & Sec | Apr 24, 2026 | Option exercise | +186 | – | – | 827 |
| Roop Kalyan Lakkaraju EVP, Chief Financial Officer | Apr 24, 2026 | Tax withholding | −420 | $287.84 | $120.89K | 2,564 |
| Roop Kalyan Lakkaraju EVP, Chief Financial Officer | Apr 24, 2026 | Option exercise | +1,078 | – | – | 2,984 |
| Melinda Litherland Pei Director | Apr 21, 2026 | Option exercise | +407 | – | – | 715 |
| Jeffrey L. Edwards Director | Apr 21, 2026 | Option exercise | +407 | – | – | 715 |
| Greg K. Hinckley Director | Apr 21, 2026 | Option exercise | +407 | – | – | 1,215 |
| Arnold A. Pinkston Director | Apr 21, 2026 | Option exercise | +407 | – | – | 715 |
| James Barry EVP, President, LSG | Nov 6, 2025 | Sale | −699.87 | $306.18 | $214.29K | 510 |
| Jonathan P. DiVincenzo President & COO | Oct 24, 2025 | Option exercise | +1,869 | – | – | 1,869 |
| Jonathan P. DiVincenzo President & COO | Oct 24, 2025 | Tax withholding | −950 | $339.75 | $322.76K | 919 |
| Sedat Evran EVP, Global Supply Chain | Oct 20, 2025 | Option exercise | +1,044 | – | – | 2,568 |
| Sedat Evran EVP, Global Supply Chain | Oct 20, 2025 | Tax withholding | −335 | $321.90 | $107.84K | 2,233 |
| Eva Anette Engelhardt EVP, President, CDG | Sep 6, 2025 | Option exercise | +1,152 | – | – | 1,309 |
| Eva Anette Engelhardt EVP, President, CDG | Sep 6, 2025 | Tax withholding | −413 | $295.43 | $122.01K | 896 |
| Colleen Corey EVP, Global Human Resources | Sep 6, 2025 | Tax withholding | −209 | $295.43 | $61.74K | 19,550 |
| Colleen Corey EVP, Global Human Resources | Sep 6, 2025 | Option exercise | +576 | – | – | 19,759 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Sep 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
–
Short volume, 20 days
68.6%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Bio-Rad Laboratories's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Alles Institute for Medical Research Corp Director, 10% Stockholder | May 28, 2026 | 700 | $219.30K | May 28, 2026 | Donation |
| Eva Anette Engelhardt Officer | May 11, 2026 | 550 | $135.60K | May 11, 2026 | Restricted Stock |
| Michael Crowley Officer | Dec 2, 2025 | 776 | $247.98K | Dec 2, 2025 | Restricted Stock |
| Alles Institute for Medical Research Corp Director, 10% Stockholder | Nov 18, 2025 | 760 | $228.79K | Nov 18, 2025 | Donation |
| James Barry Officer | Nov 6, 2025 | 701 | $214.63K | Nov 6, 2025 | Restricted Stock |
| Michael Crowley Officer | Aug 5, 2025 | 1,488 | $410.57K | Aug 5, 2025 | Restricted Stock |
| Michael Crowley Officer | Mar 13, 2025 | 3,000 | $780.00K | Mar 13, 2025 | STOCK OPTION EXERCISE |
| Alles Institute for Medical Research Corp Director, 10% Stockholder | Mar 11, 2025 | 410 | $101.54K | Mar 11, 2025 | Donation |
| Andrew J. Last Officer | Nov 6, 2024 | 3,000 | $1.12M | Nov 6, 2024 | RESTRICTED STOCK |
| Andrew J. Last Officer | Sep 12, 2024 | 1,600 | $514.50K | Sep 12, 2024 | RESTRICTED STOCK |
| Andrew J. Last Officer | Sep 6, 2024 | 3,000 | $989.82K | Sep 6, 2024 | STOCK OPTION EXERCISE |
| James Barry Officer | Sep 4, 2024 | 623 | $205.90K | Sep 4, 2024 | RESTRICTED STOCK |
| Alles Institute for Medical Research Corp Director, 10% Stockholder | Aug 27, 2024 | 990 | $308.22K | Aug 27, 2024 | Donation |
| Michael Crowley Officer | Jun 13, 2024 | 369 | $104.02K | Jun 13, 2024 | RESTRICTED STOCK |
| Timothy S. Ernst Officer | Feb 28, 2024 | 2,500 | $826.36K | Feb 28, 2024 | STOCK OPTION EXERCISE |